Exenatide is a glucagon-like peptide-1 receptor agonist, which is the first novel incretin analogues with natural glucagon-like peptide-1 activity for treatment of type 2 diabetes.[1] The common adverse effects of exenatide reported in patients include gastrointestinal disorders, pancreatic damage, hypoglycemia, and injection-site reactions. Here, GCG is linked to type 2 diabetes mellitus.